Supplemental Material: Tolerability and Efficacy of Unorthodox Dosing Regimens of Tofacitinib and Baricitinib in Pediatric Patients with Moderate to Severe Alopecia Areata

This study evaluated the efficacy and tolerability of unorthodox dosing regimens of tofacitinib and baricitinib in pediatric patients with moderate-to-severe alopecia areata over 24 weeks. The findings indicated that both drugs had comparable efficacy and were well-tolerated, with no serious adverse events. However, the unorthodox twice-daily dosing of baricitinib showed reduced efficacy compared to the guideline-recommended once-daily regimen, suggesting that deviations from standard dosing may lead to suboptimal outcomes. The study suggests that unorthodox dosing could be a short-term alternative for children who cannot tolerate standard doses, but it requires careful monitoring to ensure therapeutic effectiveness. Safety profiles were favorable, with mild adverse events and no increased risk of serious infections or cardiovascular events.